Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To determine maximum tolerated dose & dose limiting toxicity of vandetanib
when combined with standard dosing of etoposide among patients with recurrent malignant
glioma who are on & not on enzyme-inducing anti-epileptic drugs (EIAEDs) Secondary
Objectives: To assess safety & tolerability of vandetanib + etoposide in this population; To
evaluate pharmacokinetics of vandetanib among malignant glioma patients on & not on EIAEDs
when combined with etoposide.
Exploratory Objective: To evaluate for evidence of anti-tumor activity of study regimen among
recurrent malignant glioma patients including radiographic response rate, 6-month progression
free survival (PFS) rate & median PFS.